When dementia symptoms progress to the point where a doctor is considering an anti-amyloid antibody drug, APOE4 genetic testing is used to check how much risk that treatment carries for a given patient. APOE (apolipoprotein E) is a gene with several forms, or alleles, and the ε4 version is linked to a higher chance of brain swelling or bleeding on these drugs — a side effect called ARIA, for amyloid-related imaging abnormalities. The test itself doesn't diagnose Alzheimer's disease. It tells a doctor and patient what to expect from treatment and how closely to watch for trouble once it starts.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why Doctors Order the Test Before Starting Treatment
- Is the Test Required for Every Patient?
- What the Result Does and Doesn't Tell You
- How the Test Is Actually Run
- What a Doctor Should Discuss With You Before Testing
- Frequently Asked Questions
Why Doctors Order the Test Before Starting Treatment
The trigger for APOE4 testing is almost always a decision about lecanemab (brand name Leqembi) or donanemab (brand name Kisunla), the two anti-amyloid antibody drugs approved for early Alzheimer's disease. Lecanemab's FDA-approved label states that ApoE ε4 genotype testing "should be performed prior to initiation of treatment" specifically to assess a patient's risk of ARIA, according to the FDA prescribing information.
ARIA shows up on brain MRI scans as either swelling (ARIA-E) or small bleeds (ARIA-H), and most cases are mild and symptom-free. But the drug's boxed warning — the FDA's strongest safety notice — states that it can be fatal in some patients, and that people who inherited two copies of the ε4 allele (homozygotes, about 15% of Alzheimer's patients) have higher rates of both ARIA types than people with one copy or none, according to Leqembi's updated boxed warning. Because that risk difference is large enough to change how often a patient needs MRI monitoring, doctors use the test result to set the pace of follow-up imaging rather than to decide whether Alzheimer's disease is present at all.
Is the Test Required for Every Patient?
Not for every drug. Donanemab's US label describes the same genotype-risk pattern as lecanemab but does not require the test before prescribing, according to the FDA label for Kisunla.
A patient can start donanemab without knowing their APOE4 status — though their doctor then won't know whether they fall into the higher-risk homozygote group. That distinction matters in a progressing-dementia conversation: a family choosing between the two drugs may find that one path includes a mandatory genetic test and the other leaves it optional. Either way, a doctor who orders the test is doing so to calibrate monitoring, not to confirm the diagnosis that brought the patient in.
What the Result Does and Doesn't Tell You
APOE4 testing sorts patients into three groups: two copies of the risk allele (homozygous), one copy (heterozygous), or none. The homozygous group carries the highest ARIA risk of the three, which is why the lecanemab label singles it out, according to the FDA's boxed warning update. What the result does not do is confirm or rule out Alzheimer's disease.
ARUP Laboratories, which runs clinical APOE genotyping, describes the test's role as assessing ARIA risk before antibody therapy and explicitly notes that APOE status alone "neither confirms nor rules out" an Alzheimer's diagnosis, according to ARUP's test directory. Carrying ε4 raises lifetime risk of Alzheimer's at a population level, but plenty of carriers never develop the disease, and plenty of patients with Alzheimer's carry no ε4 allele at all. This is also why professional genetics guidance has, since a 2011 joint statement, recommended against routine APOE testing purely to predict Alzheimer's risk outside this treatment-decision context — a position a workgroup has been approved to revisit, though no updated guideline has been published yet, according to a summary of the NSGC/ACMG guideline.
How the Test Is Actually Run
Neither the lecanemab nor the donanemab label can point patients to an FDA-authorized APOE4 test, because none currently exists in the US. Instead, doctors order laboratory-developed tests — genotyping assays built and validated by individual labs — which the Kisunla label notes "may vary in accuracy and design" from one lab to the next, according to the FDA label.
In practice this usually means a blood draw sent for DNA analysis. A newer option is emerging outside the US: Roche received a CE mark in Europe on March 16, 2026, for the Elecsys ApoE4 Plasma test, a blood-based immunoassay the company calls the first in vitro diagnostic able to detect the ApoE4 variant directly in plasma, intended for adults already showing cognitive impairment, according to Roche's press release. Roche positions it as a first-pass screen: because roughly 40–60% of Alzheimer's patients carry at least one ε4 allele, the blood test can rule out non-carriers quickly, reserving confirmatory DNA genotyping for the smaller group of likely carriers before an antibody-therapy decision, according to Roche's clinical positioning.
What a Doctor Should Discuss With You Before Testing
Both drug labels instruct prescribers to counsel patients on what their genotype result will mean before the sample is ever drawn, since a homozygous result changes how often a patient will need MRI scans but does not change how ARIA itself is treated if it occurs, according to the FDA label for Kisunla. Questions worth raising in that conversation include: A homozygous ε4 result does not rule treatment out. It tells the care team to schedule closer imaging follow-up, since that is the group the labels flag for higher ARIA rates once treatment begins.
- Which drug is being considered, and whether that drug makes the test mandatory or optional
- How a homozygous, heterozygous, or non-carrier result would change the monitoring schedule
- What the lab's specific test reports and how its accuracy has been validated, since no two laboratory-developed tests are required to perform identically
- Whether the result will be stored or shared in a way that could affect insurance or family planning
Frequently Asked Questions
Does an APOE4 test diagnose Alzheimer's disease?
No. Laboratories that run the test note it neither confirms nor rules out Alzheimer's; it measures genetic risk for ARIA before antibody treatment, according to ARUP's test directory.
Do I need the test to take donanemab (Kisunla)?
No. Donanemab's label describes the same genotype-risk pattern as lecanemab but does not require testing before starting treatment, according to the FDA label.
Can a blood test replace DNA genotyping for APOE4?
In Europe, Roche's newly CE-marked Elecsys ApoE4 Plasma test is used to screen out non-carriers, with DNA genotyping reserved to confirm likely carriers.
